Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington’s disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Proc Natl Acad Sci U S A
Autors principals: Kaye, Joel, Piryatinsky, Victor, Birnberg, Tal, Hingaly, Tal, Raymond, Emanuel, Kashi, Rina, Amit-Romach, Einat, Caballero, Ignacio S., Towfic, Fadi, Ator, Mark A., Rubinstein, Efrat, Laifenfeld, Daphna, Orbach, Aric, Shinar, Doron, Marantz, Yael, Grossman, Iris, Knappertz, Volker, Hayden, Michael R., Laufer, Ralph
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2016
Matèries:
PNAS Plus
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5068259/
https://ncbi.nlm.nih.gov/pubmed/27671624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1607843113
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars